Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
MYCN is a transcription factor that is expressed during the development of the neural crest and its dysregulation plays a major role in the pathogenesis of pediatric cancers such as neuroblastoma, medulloblastoma and rhabdomyosarcoma. MeCP2 is a CpG methyl binding protein which has been associated w...
Main Authors: | Derek M Murphy, Patrick G Buckley, Sudipto Das, Karen M Watters, Kenneth Bryan, Raymond L Stallings |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3120883?pdf=render |
Similar Items
-
The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology
by: Kazem Nejati-Koshki, et al.
Published: (2023-05-01) -
MeCP2 binding to DNA depends upon hydration at methyl-CpG.
by: Ho, K, et al.
Published: (2008) -
MeCP2 and Chromatin Compartmentalization
by: Annika Schmidt, et al.
Published: (2020-04-01) -
Expression of the methyl-CpG-binding protein MeCP2 in rat brain. An ontogenetic study
by: Suzanne Cassel, et al.
Published: (2004-03-01) -
Neuronal non-CG methylation is an essential target for MeCP2 function
by: Tillotson, R, et al.
Published: (2021)